幸运快3
ABOUT US
Introduction
Chairman's Statement
Contact Us
R&D
R&D Platforms
R&D Capability
R&D Center
Scientific Activities
PRODUCTS
bFGF Series
other ophthalmic products
other surgical products
NEWS
company news
investee news
media focus
INVESTOR RELATIONS
Announcements & Shareholder Info
Corporate Info
Financial & ESG Reports
Contact Us
CAREERS
Talent Concept
Job Opportunities
簡
繁
EN
ABOUT US
Introduction
Chairman's Statement
Contact Us
R&D
R&D Platforms
R&D Capability
R&D Center
Scientific Activities
PRODUCTS
bFGF Series
other ophthalmic products
other surgical products
NEWS
company news
investee news
media focus
INVESTOR RELATIONS
Announcements & Shareholder Info
Corporate Info
Financial & ESG Reports
Contact Us
CAREERS
Talent Concept
Job Opportunities
簡
繁
EN
簡
繁
EN
COMPANY NEWS
Essex Bio-Technology Wins "Best Investment Value Award for Listed Companies" under China Securities Golden Bauhinia Awards Gains Wide Recognition from Capital Market for Comprehensive Strength and Investment Value
2021.12.20
First Patient First Visit Completed in the PRC in a Phase 3 Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)
2021.11.10
Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)
2021.10.27
Date
Title
2021-12-20
Essex Bio-Technology Wins "Best Investment Value Award for Listed Companies" under China Securities Golden Bauhinia Awards Gains Wide Recognition from Capital Market for Comprehensive Strength and Investment Value
2021-11-10
First Patient First Visit Completed in the PRC in a Phase 3 Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)
2021-10-27
Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)
2021-08-12
Essex Bio-Technology Reports First Half 2021 Financial Results
2021-07-25
Essex Bio-Technology Listed on Two Authoritative Lists
2021-07-19
First Patient First Visit Completed in the PRC in Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)
2021-04-30
Essex Bio-Technology Announces Upcoming Presentation at ARVO 2021 Annual Meeting
2021-04-20
Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia
Essex-Bio Group
BIOTECH
HEALTHTECH
Links
Contact us
Copyright ? 2020 Essex Bio-Technology Limited All Rights Reserved.
Disclaimer
|
Privacy Policy
This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.
ACCEPT